AVIGEN INC \DE
10-K, EX-27.1, 2000-09-27
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Previous: AVIGEN INC \DE, 10-K, EX-23.1, 2000-09-27
Next: SEPARATE ACCOUNT VA-P OF FIRST ALLMERICA FIN LIFE INSUR CO, N-4/A, 2000-09-27



<TABLE> <S> <C>

<ARTICLE> 5
<MULTIPLIER> 1,000

<S>                             <C>
<PERIOD-TYPE>                   YEAR
<FISCAL-YEAR-END>                          JUN-30-2000
<PERIOD-START>                             JUL-01-1999
<PERIOD-END>                               JUN-30-2000
<CASH>                                          13,361
<SECURITIES>                                    64,592
<RECEIVABLES>                                      940
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                                78,893
<PP&E>                                           6,959
<DEPRECIATION>                                   2,934
<TOTAL-ASSETS>                                  85,287
<CURRENT-LIABILITIES>                            2,161
<BONDS>                                          4,113
                                0
                                          0
<COMMON>                                            17
<OTHER-SE>                                        (80)
<TOTAL-LIABILITY-AND-EQUITY>                    79,013
<SALES>                                              0
<TOTAL-REVENUES>                                    58
<CGS>                                                0
<TOTAL-COSTS>                                        0
<OTHER-EXPENSES>                                17,503
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                 129
<INCOME-PRETAX>                               (15,026)
<INCOME-TAX>                                        13
<INCOME-CONTINUING>                           (15,039)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                  (15,039)
<EPS-BASIC>                                     (1.03)
<EPS-DILUTED>                                        0


</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission